-
NMPA Re-elected as a Member of the ICH Management Committee
2025-02-19
On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time.
-
Rezivertinib Mesylate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Rezivertinib Mesylate Capsules (trade name: 瑞必达) of Beta Pharma (Shanghai) Co., Ltd. is approved for marketing by China NMPA.
-
Crisugabalin Besilate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Crisugabalin Besilate Capsules (trade name: 思美宁) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with diabetic peripheral neuropathic pain.
-
Repotrectinib capsules approved with conditions for marketing by China NMPA
2024-05-11
Recently, the Class 1 innovative drug Repotrectinib Capsules (trade name: 奥凯乐/AUGTYRO) of Bristol-Myers Squibb Company is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
-
Entinostat Tablets Approved for Marketing by China NMPA
2024-04-30
Recently, the Category I innovative drug Entinostat Tablets (Chinese trade name: 景助达) of Taizhou EOC Pharma Co. Ltd was approved for marketing by the National Medical Products Administration.
-
Iptacopan Hydrochloride Capsules Approved for Marketing by China NMPA
2024-04-30
Recently, the Category I innovative drug Iptacopan Hydrochloride Capsules (trade name: FABHALTA) of Novartis Pharma Schweiz AG was approved for marketing by the National Medical Products Administration with priority review and approval, which is applicable for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.
